Beeinflusst die Verdünnung das kosmetische Ergebnis von BoNT/A?

[1]  K. Wohlfarth,et al.  Neurophysiological Double-Blind Trial of a Botulinum Neurotoxin Type A Free of Complexing Proteins , 2007, Clinical neuropharmacology.

[2]  B. Sommer,et al.  Konsensusempfehlungen zum Gebrauch von Botulinumtoxin A in der ästhetischen Medizin – Klinische Erfahrungen und Empfehlungen langjähriger Anwender , 2007 .

[3]  Soo-Keun Lee.  Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[4]  I. Zschocke,et al.  Wirksamkeit und Verträglichkeit des neuen, komplexproteinfreien Botulinumtoxins (Xeomin®) bei der Behandlung von mimischen Falten - : Untersuchungsergebnisse , 2007 .

[5]  J. Carruthers,et al.  Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter? , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[6]  A. R. Trindade de Almeida,et al.  Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  G. Borodic.  Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. , 2006, Ophthalmic plastic and reconstructive surgery.

[8]  W. Jost,et al.  Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm , 2006, Journal of Neural Transmission.

[9]  E. Růžička,et al.  A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia , 2005, Neurology.

[10]  B. Ascher,et al.  Double‐Blind, Randomized, Placebo‐Controlled, Dose‐Response Study of the Safety and Efficacy of Botulinum Toxin Type A in Subjects with Crow's Feet , 2005, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[11]  J. Carruthers,et al.  Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. , 2004, Plastic and reconstructive surgery.

[12]  K. Arndt,et al.  Effect of volume and concentration on the diffusion of botulinum exotoxin A. , 2004, Archives of dermatology.

[13]  J. Santini,et al.  A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. , 2004, Journal of the American Academy of Dermatology.

[14]  D. Dressler.  Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy , 2004, Movement disorders : official journal of the Movement Disorder Society.

[15]  J. Carruthers,et al.  Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Botulinum Toxin Type A for Patients with Glabellar Lines , 2003, Plastic and reconstructive surgery.

[16]  J. Carruthers,et al.  A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. , 2002, Journal of the American Academy of Dermatology.

[17]  C. Boake,et al.  Botulinum Toxin in Upper Limb Spasticity After Acquired Brain Injury: A Randomized Trial Comparing Dilution Techniques , 2002, American journal of physical medicine & rehabilitation.

[18]  N. Lowe,et al.  Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing , 2002, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[19]  H. Bigalke.  Botulinumtoxine: Wirksamkeit und Antigenität , 2001 .

[20]  J. Rothwell,et al.  Electromyographic Quantification of the Paralysing Effect of Botulinum Toxin in the Sternocleidomastoid Muscle , 2000, European Neurology.

[21]  A. Klein.  Dilution and Storage of Botulinum Toxin , 1998, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[22]  K. Wohlfarth,et al.  Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences , 1997, Experimental Neurology.